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Discovery of circulating proteins 
associated to knee radiographic 
osteoarthritis
Lucía Lourido1, Burcu Ayoglu2, Juan Fernández-Tajes3, Natividad Oreiro1, Frauke Henjes2, 
Cecilia Hellström2, Jochen M. Schwenk  2, Cristina Ruiz-Romero  1,4, Peter Nilsson2 & 
Francisco J. Blanco  1,5
Currently there are no sufficiently sensitive biomarkers able to reflect changes in joint remodelling 
during osteoarthritis (OA). In this work, we took an affinity proteomic approach to profile serum 
samples for proteins that could serve as indicators for the diagnosis of radiographic knee OA. Antibody 
suspension bead arrays were applied to analyze serum samples from patients with OA (n = 273), control 
subjects (n = 76) and patients with rheumatoid arthritis (RA, n = 244). For verification, a focused bead 
array was built and applied to an independent set of serum samples from patients with OA (n = 188), 
control individuals (n = 83) and RA (n = 168) patients. A linear regression analysis adjusting for sex, 
age and body mass index (BMI) revealed that three proteins were significantly elevated (P < 0.05) in 
serum from OA patients compared to controls: C3, ITIH1 and S100A6. A panel consisting of these three 
proteins had an area under the curve of 0.82 for the classification of OA and control samples. Moreover, 
C3 and ITIH1 levels were also found to be significantly elevated (P < 0.05) in OA patients compared to 
RA patients. Upon validation in additional study sets, the alterations of these three candidate serum 
biomarker proteins could support the diagnosis of radiographic knee OA.
Osteoarthritis (OA) is the most common rheumatic disease of the developed world and it is increasingly impor-
tant in current ageing populations, leading to patient chronic disability1–3. This disease manifests not only by 
cartilage degradation but also as an alteration of the whole joint structure, with progressive synovial inflammation 
and changes on the subchondral bone and osteophyte formation4.
Currently, OA diagnosis is mainly symptomatic, resting on the description of pain symptoms and stiffness of 
the affected joints, the examination of functional capacity based on Western Ontario and McMaster Universities 
Osteoarthritis Index (WOMAC)5, and the evaluation of cartilage radiography6 or magnetic resonance imaging 
(MRI)7. However, the sensitivity of radiography is not adequate for detecting small changes, thus when radio-
graphic diagnosis is established, significant joint damage has often already occurred8–10. In contrast, MRI is a 
quite sensible technique and it has been developed for the evaluation of cartilage damage in OA, but it is very 
expensive and requires a large instrumentation time, which limits its applicability8, 11. Moreover, OA has little 
efficient therapeutics, probably as a consequence of the lack of early diagnosis strategies and techniques for its 
precise monitoring.
In the last years, biochemical biomarkers have emerged as promising tools in OA diagnosis, with more sensi-
tivity and reliability than plain radiography to detect joint changes that occur in OA12. Such markers of osteoar-
thritis could facilitate early diagnosis of joint destruction, disease prognosis and progression monitoring, which 
could be detectable with an early biochemical test13. Over the years, a series of markers have been proposed that 
may reflect the synthesis or degradation of the joint tissues. However, despite the active research in this field, 
currently no single marker is sufficiently validated for its use in OA diagnosis14–16. This is mainly due to the lack 
of validation studies in large populations, which would strengthen the findings to be considered as robust bio-
markers for OA17.
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In the present study, 1032 serum samples from OA patients, healthy control subjects and disease control 
samples from patients with rheumatoid arthritis (RA) were analysed using a high-throughput affinity proteomic 
approach based on antibody suspension bead arrays, with the potential to screen hundreds of proteins in hun-
dreds of body fluid samples in parallel18. Here, we aimed to identify a panel of serum proteins able to discriminate 
knee radiographic OA patients from healthy controls. The specificity of the proteins found was evaluated by 
screening the protein profiles of RA patients.
Results
Initial screening phase. An overview of the strategy followed in this work for the large-scale proteomic 
analysis of sera is illustrated in Fig. 1. In the screening phase, we analysed a sample set composed of 273 OA, 
76 controls and 244 RA subjects using a suspension bead array composed of 174 different antibodies targeting 
78 different proteins (Array 1, Supplementary Table S1). Three proteins displayed levels significantly (P < 0.05) 
different between OA patients and healthy controls (Fig. 2), whereas 33 differed between OA and RA patients 
(Fig. 1). Among these, two proteins identified as distinguishing between OA and controls were also quantitatively 
different between OA patients compared to RA patients (Fig. 1). The results of this screening phase narrowed 
the list of candidates to 34 different proteins. Therefore, a more focused array comprising a total of 79 antibodies 
targeting these 34 proteins (Array 2, Supplementary Table S2) was used to profile the same set of samples. All 
the results were confirmed using this new array in the screening set (Supplementary Table S3A and S3B), which 
demonstrated the robustness of the technology and the reliability of the data obtained.
Verification phase. Following the screening phase, a verification study was performed to profile the panel of 
these 34 proteins (Array 2) in an independent set of serum samples from 188 OA patients and 83 control subjects, 
as well as 168 RA patients (Table 1). In accordance with the findings observed in the screening phase, the same 
three proteins identified in the screening analyses were found to display levels allowing to significantly (P < 0.05) 
distinguish between OA and healthy individuals (Figs 1 and 2). Additionally, 30 proteins out of the 33 detected 
in the screening were verified as differing between OA and RA patients, being two of these 30 also modulated 
between OAs and Controls (Fig. 1, Supplementary Table S4A and S4B).
Figure 1. Schematic overview of the study. A screening phase was performed using a set of 593 serum samples 
and a protein array composed of 174 antibodies targeting 78 different proteins (Array 1, Phase I.I.). The levels 
of three proteins were found significantly (P < 0.05) different between osteoarthritis (OA) patients and control 
individuals, and 33 proteins differed between OA and rheumatoid arthritis (RA). A more focused array (Array 
2) was then built targeting these 34 different proteins with 79 antibodies, and the results were replicated in 
the same sample set (Phase I.II.). Finally, a verification phase (II) was carried out using this second array on 
an independent set of 439 serum samples. In this phase, the three biomarker candidates separating OA and 
controls were verified, as well as 30 of the 33 proteins that were found with altered levels between OA and RA 
patients.
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Protein profiles for OA diagnosis. The screening and verification phases concordantly allowed the iden-
tification of three antibodies targeting three different proteins that revealed significant differences in abundance 
(P < 0.05) between radiographic knee OA patients and control individuals. These three antibodies were gener-
ated towards complement 3 (C3), inter-alpha trypsin inhibitor heavy chain 1 (ITIH1) and S100 calcium binding 
protein A6 regulator (S100A6). All of these three proteins showed higher levels in serum from OA patients when 
compared to the control group (Fig. 2).
The classification power of the identified and concordant protein profiles was visualized by a receiver operator 
characteristic (ROC) curve in the two sample sets combined. As shown in Fig. 3, this protein panel had an area 
under the curve (AUC) >0.82 for the classification between all OA patients and controls used in this study.
Proteins associated with radiographic severity. After the identification of the protein panel concord-
antly distinguishing between OA patients and healthy controls in the two sample cohorts analysed separately 
(Fig. 2), both sample sets were combined to compare the profiles of C3, ITIH1 and S100A6 between the different 
OA K/L scored groups and healthy controls used in this study. A normalization step was followed to enable the 
combination of data from the two cohorts (see Methods), which was needed to provide a more homogeneous 
range of K/L grades for the comparisons. As shown in Fig. 4, patients with K/L = 2 showed significantly higher 
serum levels of C3, ITIH1 and S100A6 compared to controls. The same profiles were observed in the comparison 
between K/L = 3 and controls for C3 and S1006. Interestingly, significant differences were found already in OA 
Figure 2. Identification of concordant protein profiles separating osteoarthritis patients from control groups 
in the screening and verification sample sets analysed separately. Box-plots illustrate the profiles for the three 
proteins concordantly revealing significant differences (P < 0.05) in the two sample sets analysed in this 
study for group comparisons between OA patients and controls. For each sample group, the box-and-whisker 
plot represents MFI values within lower and upper quantile (box), the median (horizontal line within box), 
percentiles of 5% and 95% (whiskers) and outliers (dots).
Screening set Control
OA = 273
RAK/L = 2 K/L = 3 K/L = 4
Number of subjects 76 110 106 57 244
Female (%) 55 74 86 88 75
BMI, kg/m2 (mean ± SD) 29 ± 6 31 ± 5 32 ± 6 32 ± 5 27 ± 5
Age, years (mean ± SD) 63 ± 9 66 ± 8 69 ± 9 69 ± 10 55 ± 14
Verification set Control
OA = 188
RAK/L = 2 K/L = 3 K/L = 4
Number of subjects 83 38 27 123 168
Female, % 59 76 78 78 74
BMI, kg/m2 (mean ± SD) 25 ± 4 31 ± 5 31 ± 4 32 ± 5 27 ± 5
Age, years (mean ± SD) 54 ± 19 67 ± 11 71 ± 7 71 ± 8 58 ± 12
Table 1. Clinical characteristics of the patients and control subjects used in the study. BMI, indicates body mass 
index; K/L, Kellgren-Lawrence score and SD, standard deviation.
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K/L = 2 compared to healthy controls for all the three proteins. Only S100A6 showed higher levels in all K/L cat-
egories (K/L = 2, K/L = 3 and K/L = 4) compared to healthy controls (Fig. 4).
Proteins distinguishing OA and RA patients. The analysis of the screening and verification phases also 
allowed the detection of 30 proteins that significantly (P < 0.05) and concordantly differed between OA and RA 
patients in the two sample sets (Supplementary Table S4B). Among these 30 proteins, 18 were increased and 12 
were decreased in OA patients compared to RA individuals. The classification performance of the identified and 
concordant protein profiles was visualized by a receiver operator characteristic (ROC) curve. The protein panel 
composed of these 30 proteins showed an area under the curve (AUC) >0.93 for classification between all OA 
and RA patients used in this study (Fig. 5A). The predicted biological roles of these proteins are represented in 
Supplementary Table S5, showing that 30% of them are related to inflammatory processes, 20% associated to 
bone remodelling, 20% involved in extracellular matrix (ECM) stability, 14% related to lipid metabolism and 16% 
implicated in other biological functions such as cell proliferation and transmembrane transport.
Finally, among the 30 proteins differing between OA and RA patients, we found that the levels of C3 and 
ITIH1, the two proteins significantly elevated in OA compared to controls (Fig. 2), were also significantly 
increased in OA patients compared to RA individuals (Fig. 5B).
Discussion
We have performed an extensive profiling of serum samples using two different suspension antibody bead 
arrays with the aim of identifying protein profiles that could be associated with OA. Serum samples from a total 
of 1,032 individuals were analysed to evaluate the levels of up to 78 different proteins. To our knowledge, this 
high-throughput technology has been applied for the first time for the analysis of serum sample collections of 
this size within OA.
Using this high throughput and multiplex affinity proteomic approach, we identified three proteins (C3, 
ITIH1 and S100A6), whose levels in serum were significantly increased between radiographic OA and control 
individuals. These three proteins are therefore likely to be potential biochemical markers for this disease.
To evaluate the specificity of the protein panel, we analyzed samples from another rheumatic disease (RA) 
along with OA and controls. Interestingly, among the significantly modulated proteins, we found that two pro-
teins, C3 and ITIH1 were concordantly and significantly increased in OA compared to both healthy controls d 
RA patients. Complement components are expressed by normal chondrocytes and their production is increased 
in the presence of fragments of extracellular matrix components. It is known that in OA the catabolic processes 
compromise the integrity of the cartilage, and fragments of proteins released from ECM as fibromodulin, COMP 
and osteoadherin lead to the activation of C1q component to further activate the classical and alternative path-
ways of complement factors19.
Low-grade inflammation is a feature already described in the literature as a driving force in the pathogenesis 
of the OA20, 21 and it is known that the inflammatory complement system plays a central role within this process22. 
Complement activation has also emerged as a crucial factor in experimental OA progression23. Increased levels of 
complement C3 in serum from late OA patients compared to healthy donors were already identified in previous 
proteomic screenings24. Furthermore, one of its fragments (C3f) was also described as increased in early OA 
compared to normal individuals and RA patients25.
In the present work, we have found that protein C3 levels are higher in serum from OA compared to all con-
trol subjects (healthy and RA), being significant higher when less severe OA stages (K/L = 2) were compared to 
Figure 3. ROC curve representing the classification power of a panel composed of C3, ITIH1 and S100A6 
profiles to discriminate between all OA patients and healthy control individuals analysed in this study.
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healthy controls but they decrease when OA progresses (K/L = 3 and K/L = 4). Our results obtained for serum are 
in agreement with what has been already observed in synovial fluids22.
Taken together, we may speculate that C3 appeared to be increased in OA compared to healthy controls, but it 
decreases when OA progresses because the activation of complement cascade could be the main driver of inflam-
mation at the first stages of the OA but at end stages (K/L = 4), this inflammatory pathway might switch to other 
biochemical pathways more associated to advanced OA and chronic arthritis such as RA.
An interesting data to support this hypothesis would be that in this work we also observed that levels of 
C3, together with other complement proteins, were significantly increased in OA patients compared to RA 
(Supplementary Table S5), which is a rheumatic disease more characterized by chronic and systemic inflamma-
tion than OA.
Therefore, using an antibody-based approach, our result confirms previous data described in the literature and 
point out the potential of C3 evaluation as an early marker of radiographic knee OA.
Figure 4. Box-plots showing the differential profiles of the three proteins between healthy controls and the 
different OA K/L groups from the two samples sets (screening and verification sets) combined. For each sample 
group, the box-and-whisker plot represents MFI values within lower and upper quantile (box), the median 
(horizontal line within box), percentiles of 5% and 95% (whiskers) and outliers (dots). Comparisons indicated 
with an * were statistically significant (P < 0.05).
Figure 5. (A) ROC curve demonstrating the classification power of the panel of 30 proteins identified in this 
study for the classification between all OA patients and RA individuals included in the study. (B) Box-plots 
showing the two proteins revealing significant differences between OA patients and controls, which also 
revealed significant differences (P < 0.05) between OA and RA patients. For each sample group, the box-and-
whisker plot represents MFI values within lower and upper quantile (box), the median (horizontal line within 
box), percentiles of 5% and 95% (whiskers) and outliers (dots).
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We also found that the levels of inter-alpha-trypsin inhibitor heavy chain 1 (ITIH1) were higher in OA 
patients compared to healthy controls and RA individuals. This protein also showed higher levels in all OA K/L 
grades compared to controls, although this was only statistically significant in K/L = 2 and K/L = 4 scores. It is 
known that ITIH1 is synthesized by chondrocytes and binds to hyaluronic acid and other extracellular matrix 
components26, 27 providing stability to the cartilage. This protein was found at higher levels in synovial fluids 
from OA patients compared to RA28, and this trend has been also detected in serum in the present work (Fig. 4). 
Therefore, our results show for the first time evidence in serum of the role of ITIH1 in OA and its potential value 
as a molecular signature of this disease.
Besides the additional evidence of the role of complement activation and ITIH1 in OA, our study also provides 
new insights into other pathogenic mechanisms of this disease. The identification of significantly increased levels 
of S100A6 (or calcyclin) in all K/L groups of OA serum samples compared to healthy controls points to a role of 
this protein in the OA process. Although this calcium-binding protein is known to be expressed in OA cartilage29 
and there is an evidence of its expression in chondrocytes (data shown in HPA database, www.proteinatlas.org), 
its role in OA cartilage has so far not been described. It has been suggested that S100A6 could be involved in cell 
survival by interaction with advanced glycation end products (RAGE), consequent formation of reactive oxygen 
species (ROS), activation of ERK pathway and changes in NF-κB transcriptional activity, as well as promoting 
catabolic process in the cartilage30, 31. S100A6 was also described to enhance osteoblast proliferation and bone 
remodelling, however the underlying mechanisms are still unclear32. Therefore, our results suggest a potential 
value of this protein for diagnosis of OA, and underline the need of further functional studies to elucidate the 
specific role of S100A6 in OA.
In conclusion, we present for the first time an affinity proteomic approach comparing serum protein levels of 
OA, control and RA individuals in a total of 1,032 samples. Among the 78 different investigated proteins, targeted 
with 174 antibodies, we identified three proteins: Levels of C3, ITIH1 and S100A6 significantly differed between 
OA patients and healthy individuals, with the potential to be of additive value for the diagnosis and monitoring 
of OA. Interestingly, the serum levels of two of these proteins, C3 and ITIH1, differed also among OA and RA 
patients, which suggest C3 and ITIH1 are proteins specifically increased in OA. Taken together, upon further 
validations in independent sample collections, these findings help to a better understanding of OA pathology and 
provide a novel insight into the OA biomarker field.
Methods
Ethic statement. All methods were conducted according to the Declaration of Helsinki, which establish the 
regulations and guidelines for research project execution for human health. The research protocol was approved 
by the local Ethics Committee (Comité Ético de Galicia, Galicia, Spain). An informed written consent was 
obtained from all participants. The cohorts of patients included in this project were selected from the collections 
of samples already available and characterized at the Biobank of INIBIC, Collection of samples for research in 
Rheumatic Diseases (Cod. RNB C.0000424).
Patients and controls. All individuals analysed in this study are included in specific cohorts localized in the 
Rheumatology Service of Hospital Universitario of A Coruña. All these individuals came at the Rheumatology 
Service of the Hospital to perform a regular clinical visit. The OA participants (n = 461) were diagnosed accord-
ing to the American College of Rheumatology (ACR) criteria33, which exclude a disease of autoimmune etiology. 
and knee radiographies were classified using the Kellgren-Lawrence (K/L) score34. All patients with knee OA who 
tested positive for the autoantibodies rheumatoid factor, anti-nuclear (ANA) and anti-citrullinated antibodies 
(anti-CCP), were excluded from the study. Individuals were classified as controls (n = 159) based on follow-
ing inclusion criteria: not autoimmune disease and non-radiographic knee OA. Additionally, a total of 412 RA 
patients fulfilling the ACR criteria35, were included in the study. The clinical data of the patients are summarized 
in Table 1.
Samples. Blood samples from all patients and controls were collected after overnight fast in plain tubes con-
taining a separation gel. The samples were allowed to stand for 20 min and then centrifuged at 2800 rpm for 
10 min. The serum was aliquoted and stored at −80 °C until use.
Antibody selection and bead array generation. Protein targets proposed to generate the antibody 
bead arrays were selected based on thorough mining of experimental evidence in the literature of rheumatic 
diseases36–38 and in previous in-house efforts in the field of osteoarthritis using mass spectrometry analyses24, 28, 39. 
The antibody set was finally designed according to the antibody availability within the Human Protein Atlas 
(HPA)40. A total of 174 protein microarray-validated polyclonal antibodies41 targeting 78 unique proteins were 
included in the arrays, selecting at least one antibody for each target protein (Supplementary Table S1).
The bead arrays were created as previously described42, 43 by diluting 1.6 μg of each antibody into 100 μL of anti-
body dilution buffer. All antibodies were immobilized onto color-coded magnetic beads (MagPlex-C, Luminex 
Corp.) with each bead identity corresponding to a unique antibody. The coupling of each antibody on the beads 
was confirmed via R-phycoerythrin-conjugated donkey anti rabbit-IgG antibody (Jackson ImmunoResearch).
Serum profiling. The procedure for serum profiling was performed as described previously43, 44. Briefly, 3 μL 
of each sample were diluted 1:10 in phosphate-buffered saline (PBS), and randomized in 96-well plates. Then, 
the protein content was directly labelled with biotin (Life Technologies). Samples were further diluted 1:50 in an 
assay buffer, heated for 30 min at 56 degrees Celsius for 30 min, combined into a 384-well microtiter plate, and 
incubated with the bead array at room temperature on a shaker overnight. Unbound proteins were removed by 
washing and proteins captured on the beads were detected through a R-phycoerythrin-conjugated streptavidin 
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(Invitrogen). Results from the FlexMap3D instrument (Luminex Corp.) were reported per bead identity as 
median fluorescence intensities (MFI).
Study setup. An overview of the study design is illustrated in Fig. 1. A set of 593 samples (denoted as 
screening set) containing 273 OA patients, 76 control subjects and 244 RA patients was first analyzed (screen-
ing phase) using a panel of 174 antibodies immobilized on bead arrays, targeting 78 unique proteins (Array 1, 
Supplementary Table S1). In total, 34 different proteins showed altered levels in comparisons across the sample 
groups in this first screening. Secondly, a smaller panel comprising 79 antibodies targeting these 34 proteins 
(Array 2, Supplementary Table S2) was used to replicate the analysis on the same screening set, and then in a third 
step to verify the protein profiles identified in this screening phase using a new set of 439 samples (denoted as 
verification set), which was composed of 188 OA, 83 controls and 168 RA individuals.
Statistical analysis. Data were processed and visualized in R. MFI values were normalized in each 384-plate 
by probabilistic quotient normalization (PQN) as accounting for any potential sample dilution effects45. In addi-
tion, potential batch effects were adjusted using the ComBat function included in the ‘sva’ R package. The outliers 
that were identified by robust principal component analysis (rPCA, R package “rrcov”) were excluded from fur-
ther analysis.
The technical variation was assessed by calculating the coefficient of variation (C.V.), which was lower than 
20% based on replicates of pooled samples distributed across all the plates (Supplementary Figure S1).
For biological interpretation, a linear regression analysis adjusting for sex, age and body mass index (BMI) was 
applied as a statistical test in order to identify differences in protein profiles between the compared groups (Figs 2 
and 5B). Proteins were denoted significantly different between groups if the antibodies targeting each specific 
protein revealed unadjusted P < 0.05 both in screening and verification phases analysed separately.
We employed logistic regression to evaluate the classification power of the significant proteins concordantly 
distinguishing OA and controls (Fig. 3), as well as between OA and RA patients in the combination of the two 
sample sets (Fig. 5A), where ten-fold cross-validation method was selected as cross-validation option. The ROC 
curves were generated using the R package “pROC”.
For the K/L analysis, the two cohorts were combined to obtain a better range of K/L grades. The differences 
between both cohorts were minimised by dividing all MFI values in each cohort by the overall median MFI of 
the corresponding cohort. Before combining the two cohorts, a log2-scaling was performed to approximate the 
distribution of different antibodies in each cohort to the normal and, thus, to make them more alike. Finally, a 
linear regression analysis adjusting for sex, age and body mass index (BMI) was applied as a statistical test in order 
to identify differences in protein profiles between the different K/L grades and the controls (Fig. 4).
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